Merck KGaA said the FDA approved a rare noncancerous joint tumor therapy it had licensed from Abbisko, a China-based biotech. The approval gives Merck a regulatory foothold in a niche indication, creating a new revenue and lifecycle opportunity tied to rare disease adoption. For Abbisko, the deal reflects a common late-stage pathway in rare oncology/benign tumor areas: partnering early, then transferring regulatory execution once efficacy and safety support approval. The development is notable for investors tracking how cross-border licensing is translating into U.S. access—especially when the asset’s label focus aligns with orphan-style commercial economics. The provided item did not include additional clinical data or financial terms, but an FDA approval typically triggers launch planning and post-marketing evidence generation.